Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADYX OTCMKTS:AFFY OTCMKTS:ANTH OTCMKTS:XYNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADYXAlliqua BioMedical$0.00+∞$0.00$0.00▼$0.00N/A1.9818 shs2,200 shsAFFYAffymax$0.00$0.00$0.00▼$0.00N/A7.3411,222 shs500 shsANTHAnthera Pharmaceuticals$0.00$0.00$0.00▼$0.00N/A1.828,907 shs965 shsXYNOXynomic Pharmaceuticals$2.22$2.22$0.20▼$3.84N/AN/AN/AN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADYXAlliqua BioMedical0.00%0.00%0.00%0.00%0.00%AFFYAffymax0.00%+14.29%0.00%0.00%+14.29%ANTHAnthera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%XYNOXynomic Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADYXAlliqua BioMedical 0.00N/AN/AN/AAFFYAffymax 0.00N/AN/AN/AANTHAnthera Pharmaceuticals 0.00N/AN/AN/AXYNOXynomic Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADYXAlliqua BioMedicalN/AN/A0.00∞N/AN/AN/AN/AN/AAFFYAffymaxN/AN/A0.00∞N/AN/AN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADYXAlliqua BioMedicalN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADYXAlliqua BioMedicalN/AAFFYAffymaxN/AANTHAnthera PharmaceuticalsN/AXYNOXynomic PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADYXAlliqua BioMedical17.40%AFFYAffymax1.55%ANTHAnthera Pharmaceuticals2.08%XYNOXynomic Pharmaceuticals86.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADYXAlliqua BioMedical6N/AN/ANot OptionableAFFYAffymax4N/AN/ANot OptionableANTHAnthera Pharmaceuticals20N/AN/ANot OptionableXYNOXynomic Pharmaceuticals27N/AN/ANot OptionableXYNO, AFFY, ADYX, and ANTH HeadlinesRecent News About These Companiesindian cricket team t20 world cupDecember 28, 2024 | bwhotelier.businessworld.inBFollicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightNovember 29, 2024 | finance.yahoo.comAbexinostat by Xynomic Pharmaceuticals for Follicular Lymphoma: Likelihood of ApprovalSeptember 10, 2024 | pharmaceutical-technology.comPAbexinostat by Xynomic Pharmaceuticals for High-Grade Glioma: Likelihood of ApprovalSeptember 9, 2024 | pharmaceutical-technology.comPAbexinostat by Xynomic Pharmaceuticals for Anaplastic Astrocytoma: Likelihood of ApprovalSeptember 9, 2024 | pharmaceutical-technology.comPGame-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsightAugust 6, 2024 | finance.yahoo.comAbexinostat by Xynomic Pharmaceuticals for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of ApprovalMay 17, 2024 | pharmaceutical-technology.comPFull-Time MBA concentration in Pharmaceutical ManagementApril 28, 2024 | business.rutgers.eduBGlioblastoma Pipeline Landscape Report 2024: Pivotal Advances in Treatment Protocols and Drug DevelopmentsApril 26, 2024 | finance.yahoo.comNon-Hodgkin Lymphoma Pipeline Landscape 2024: Analysis of Over 220 Potential Pharmaceuticals in DevelopmentApril 25, 2024 | finance.yahoo.comWatson PharmaceuticalsFebruary 21, 2024 | forbes.comElite Pharmaceuticals Inc.February 14, 2024 | wsj.comHDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJanuary 8, 2024 | finance.yahoo.comFennec Pharmaceuticals Inc FENCNovember 1, 2023 | morningstar.comMStarfield:PharmaceuticalsSeptember 26, 2023 | videogamer.comVDelveInsight Highlights Major Advances, Transformative Therapies, and 195+ Leading Players Wheeling the Glioblastoma Clinical Trial Pipeline LandscapeSeptember 1, 2023 | benzinga.comGlaxosmithkline PharmaceuticalsJuly 8, 2023 | livemint.comCompany History - Paam PharmaceuticalsMay 30, 2023 | moneycontrol.comGlenmark Pharmaceuticals Get USFDA Nod For Human Trial Of Advanced Cancer-Treating DrugMarch 18, 2023 | outlookindia.comDelveInsight Evaluates a Robust High-grade Glioma Pipeline as 120+ Influential Pharma Players to Set Foot in the DomainMarch 13, 2023 | finance.yahoo.comMedia Sentiment Over TimeXYNO, AFFY, ADYX, and ANTH Company DescriptionsAlliqua BioMedical OTCMKTS:ADYX$0.0001 +0.00 (+∞) As of 07/15/2025 05:20 PM EasternAdynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.Affymax OTCMKTS:AFFY$0.0008 0.00 (0.00%) As of 12:17 PM EasternAffymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.Anthera Pharmaceuticals OTCMKTS:ANTH$0.0001 0.00 (0.00%) As of 09:39 AM EasternAnthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.Xynomic Pharmaceuticals OTCMKTS:XYNO$2.22 0.00 (0.00%) As of 06/23/2021Xynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
